Ami Organics IPO notes ⚗️

Supplies Raw materials (Intermediates) to API players (7% of revenues from Laurus Labs for example)

Hit the 'retweet' & help us educate more investors

A Thread 🧵👇
1/ Basics about the IPO.

Raising 200crs of Fresh Issue (& OFS of 370crs): will be used for repayment of debt & WC

MCap at 2200crs: EV/S of 6 & EV/EBITDA of 26 (stretched for an unknown company)

Promoters only hold 41% after the IPO
2/ An Pharma intermediates player that sells to API players focusing on high-growth therapeutics.

Caters to 150 customers (incl. Laurus, Cadila & MNC players, etc) | 50% exports
3/ R&D Expertise: Market leader across many intermediates | 66 R&D Personnel | 8 Process Patents | 1-2% of rev

High Entry Barriers due to the complex chemistries

The capacity of 6060 MTPA (3600MTPA recently through inorganic): old plant of 2460 MTPA at 60% utilisation
4/ Breakup of the rev 👇

Could be helpful in tracking how the offtake of other companies are; for ex: they supply intermediates of Dolutegravir to Laurus Labs.
5/ 5 customers account for 44% of the rev: Concentration risk; any change in end product offtake will have reverberations into their P&L.

GMs have increased from 33% to 45% in 3yrs: Might not be sustainable
6/ Acquired the incremental 3600 MTPA capacity for just 93crs; ability to scale up with higher value products is a key trackable.
7/ Financials:

High Working capital requirements: weak cash flow conversion | High Asset Turnover ensures a good return on capital

Revenue growth might sustain as the new plants ramp up, although margins look to be on the higher side (Gross margins look subnormal)
8/ Risks:

- Unlisted group company into APIs which wasn't mentioned in the IPO prospectus; check out the tweets below by @arpit971 & @tusharbohra
- Any adverse USFDA reaction
- Not clear if they can pass on the RM price increases

- Operations are dependent on the ability to collaborate & innovate; a key trackable
- Newly acquired plants (60% of total capacity) from Gujarat Organics might not yield effective results.
- Product concentration risks: 40-45% of rev from 2 products 👇


Better be cautious rather than aggressive in betting on a new company (not to forget, in a sector which is currently valued as if nothing can go wrong) with so many unknowns; even the valuations are not in our favour.

Comparison with the peers 👇

End of Thread.
Edit: They have mentioned their group company "Ami Lifesciences" which is into APIs in their RHP.

• • •

Missing some Tweet in this thread? You can try to force a refresh

Keep Current with ᴀɴɪsʜ ᴍᴏᴏɴᴋᴀ

ᴀɴɪsʜ ᴍᴏᴏɴᴋᴀ Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!


Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @AnishA_Moonka

13 Sep
Top 5 global pharma cos. (by rev)

J&J- $83B
Roche- $55B
Novartis- $49B
Merck- $48B
Pfizer- $42B

Top 5 Indian Pharma cos. (by rev)

Sun- $4.7B
Aurobindo- $3.3B
Cipla- $2.7B
Dr Reddys- $2.6B
Cadila- $2.1B

$1.6T market by FY25, Not investing in 🇮🇳's pharma growth story is a risk.
What makes us optimistic? $236B worth of innovator drugs patent expiry to happen in the next 4-5yrs.

Who are the most competitive players that will gobble up the opportunity? Indian Pharma cos.

Whether be it biosimilars or complex generics.

Src- Care Ratings
The costs of production in India is 50% cheaper than the developed markets

The cost of R&D is 1/8th the developed markets

The cost of clinical trials is 1/10th the developed markets.

+ Trained & specialized pharma workforce.
Read 7 tweets
9 Sep
All the companies in the Cement Fibre Products Industry have given huge returns in the past year 👇

Let's understand what drives the industry & the risks.

Hit the 'retweet' to help us educate more investors.

A Thread 🧵
1/ The Indian roofing industry is worth Rs 42,000 Crores and is expected to grow at the rate of 6-8% cagr.

So, What are the different options & what sets them apart?
2/ Among the pucca houses, less than half use RCC slabs; the rest utilize ready-to-use house roofing products (fiber cement roofing/ metal roofing).

Comparison between different options 👇

Now, this clears the superiority of Fiber Cement Sheets, let move further.
Read 19 tweets
2 Sep
Semiconductor shortages are creating some fantastic opportunities in the broader stock market; think FY24 & swing the bat.
On the contrary, the current supply crunch will help the OEMs to pass on the increased RM costs.

This will reflect in the bottom line & gross margins (OEMs have seen a 6-7% reduction from FY18) when this normalizes.
High uncertainty in the short term is the best friend of a long-term patient investor.

Look for companies that have high operating leverage play (including financial leverage), are not being talked about in the investment circles & where the promoters have everything to lose.
Read 4 tweets
24 Aug
"We are carrying Rs 27,936 crore of fixed-rate liabilities at 8.66%, largely legacy, and you can imagine the upsides when these are replaced by low-cost deposits." ~ V. Vaidyanathan, IDFC First Bank FY21 AR.
"We advise our product teams to design products in such way that it is meant to be sold to our 'near and dear' ones. We make products with transparent pricing and fees."
"We don’t pressurize our employees to 'somehow' sell high-margin products to meet fee targets. The list of our 'Customer First' features is long."
Read 14 tweets
3 Aug
Krsnna Diagnostics IPO notes: 'Let's do Good' ❓

Hit the 'retweet' & help us educate more investors

A thread 🧵👇

1/ Basics about the IPO

Issue Dates: 4 - 6 August
Issue Size: ₹ 1,211 Crore (400crs Fresh Issue & 811crs OFS)
Mcap at the upper band: 2994crs
Price Band: ₹ 933 - 954
Retail Quota: 10%

Promoter stake to go from 32% to 27% post IPO.
2/ About the company.

Krsnaa Diagnostics provides technology-enabled services such as imaging (including radiology), pathology/clinical laboratory, and teleradiology

to public and private hospitals, medical colleges and community health centres across India.
Read 13 tweets
31 Jul
Windlas Biotech IPO notes 💊

'What's in a name? that which we call a rose by any other name would smell as sweet' ~Shakespeare

Hit the 'retweet' & help us educate more investors

A thread 🧵👇

1/ Basics about the IPO 👇

Incorporated in 2001

Fresh Issue of 165crs (50 for capex | 48 for Working capital | 20 for debt payment) + OFS of 237crs (Partially by promoter & PE Tano selling out as the fund tenure is up)

~ Total raise of 402crs
2/ About the company (Not a Biotech company)

A Contract manufacturer for formulation cos. (204 in total) for Indian markets & a small domestic OTC biz

3279 products, 4 plants with 700cr tablets/capsules capacity

Emphasis on chronic (60% of rev) & complex generics (70% of rev)
Read 15 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!